Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abcam plc stock logo
ABCZF
Abcam
C$22.25
C$22.25
C$5.00
C$23.80
N/AN/A2,659 shsN/A
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
$0.00
$0.00
$0.00
N/AN/A11,650 shs9,999 shs
4Front Ventures Corp. stock logo
FFNTF
4Front Ventures
$0.00
$0.00
$0.07
N/AN/A1.28 million shsN/A
Sanofi stock logo
SNYNF
Sanofi
$85.25
$86.87
$80.74
$106.34
N/AN/A20,374 shs4,535 shs
7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abcam plc stock logo
ABCZF
Abcam
0.00%0.00%0.00%0.00%0.00%
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
0.00%0.00%0.00%0.00%0.00%
4Front Ventures Corp. stock logo
FFNTF
4Front Ventures
0.00%0.00%0.00%0.00%-93.75%
Sanofi stock logo
SNYNF
Sanofi
+0.64%+1.05%-2.81%-10.52%-13.31%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abcam plc stock logo
ABCZF
Abcam
C$22.25
C$22.25
C$5.00
C$23.80
N/AN/A2,659 shsN/A
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
$0.00
$0.00
$0.00
N/AN/A11,650 shs9,999 shs
4Front Ventures Corp. stock logo
FFNTF
4Front Ventures
$0.00
$0.00
$0.07
N/AN/A1.28 million shsN/A
Sanofi stock logo
SNYNF
Sanofi
$85.25
$86.87
$80.74
$106.34
N/AN/A20,374 shs4,535 shs
7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abcam plc stock logo
ABCZF
Abcam
0.00%0.00%0.00%0.00%0.00%
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
0.00%0.00%0.00%0.00%0.00%
4Front Ventures Corp. stock logo
FFNTF
4Front Ventures
0.00%0.00%0.00%0.00%-93.75%
Sanofi stock logo
SNYNF
Sanofi
+0.64%+1.05%-2.81%-10.52%-13.31%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abcam plc stock logo
ABCZF
Abcam
0.00
N/AN/AN/A
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
0.00
N/AN/AN/A
4Front Ventures Corp. stock logo
FFNTF
4Front Ventures
0.00
N/AN/AN/A
Sanofi stock logo
SNYNF
Sanofi
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abcam plc stock logo
ABCZF
Abcam
N/AN/AN/AN/AN/AN/A
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
N/AN/AN/AN/AN/AN/A
4Front Ventures Corp. stock logo
FFNTF
4Front Ventures
N/AN/AN/AN/AN/AN/A
Sanofi stock logo
SNYNF
Sanofi
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abcam plc stock logo
ABCZF
Abcam
N/AC$0.17130.73N/AN/AN/AN/AN/AN/A
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
N/A-$0.16N/AN/AN/AN/AN/AN/AN/A
4Front Ventures Corp. stock logo
FFNTF
4Front Ventures
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Sanofi stock logo
SNYNF
Sanofi
N/A$3.0827.64N/AN/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Abcam plc stock logo
ABCZF
Abcam
C$0.070.32%N/A42.48%N/A
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
N/AN/AN/AN/AN/A
4Front Ventures Corp. stock logo
FFNTF
4Front Ventures
N/AN/AN/AN/AN/A
Sanofi stock logo
SNYNF
Sanofi
$2.803.28%N/A90.78%N/A

Institutional Ownership

CompanyInstitutional Ownership
Abcam plc stock logo
ABCZF
Abcam
43.58%
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
32.45%
4Front Ventures Corp. stock logo
FFNTF
4Front Ventures
N/A
Sanofi stock logo
SNYNF
Sanofi
30.06%

Insider Ownership

CompanyInsider Ownership
Abcam plc stock logo
ABCZF
Abcam
N/A
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
N/A
4Front Ventures Corp. stock logo
FFNTF
4Front Ventures
N/A
Sanofi stock logo
SNYNF
Sanofi
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Abcam plc stock logo
ABCZF
Abcam
1,750N/AN/ANot Optionable
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
N/AN/AN/ANot Optionable
4Front Ventures Corp. stock logo
FFNTF
4Front Ventures
460N/AN/ANot Optionable
Sanofi stock logo
SNYNF
Sanofi
91,600N/AN/ANot Optionable

Recent News About These Companies

Sanofi (OTCMKTS:SNYNF) Sees Large Drop in Short Interest
Deutsche Bank Keeps Their Buy Rating on Sanofi (SNYNF)
Jefferies Reaffirms Their Buy Rating on Sanofi (SNYNF)
UBS Keeps Their Hold Rating on Sanofi (SNYNF)
Sanofi (SNYNF) Gets a Hold from J.P. Morgan
Deutsche Bank Reaffirms Their Buy Rating on Sanofi (SNYNF)
UBS downgrades Sanofi (SNYNF) to a Hold

New MarketBeat Followers Over Time

Media Sentiment Over Time

Abcam stock logo

Abcam OTCMKTS:ABCZF

C$22.25 0.00 (0.00%)
As of 07/6/2026

Abcam Limited, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. The company's principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, biochemicals, and cell signaling pathway tools. It serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. The company has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. It sells its products online. Abcam Limited was formerly known as Abcam plc and changed its name to Abcam Limited in December 2023. The company was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom. As of December 6, 2023, Abcam Limited operates as a subsidiary of Danaher Corporation.

Abattis Bioceuticals stock logo

Abattis Bioceuticals OTCMKTS:ATTBF

Abattis Bioceuticals Corp. operates as a life sciences and biotechnology company in Canada. The company develops and licenses natural health products, medicines, extractions, and ingredients for the biological, nutraceutical, bioceutical, and cosmetic markets. It also provides Comfort, a cannabinoid enhanced nutraceutical for pain and inflammation; and Health-Canada licensed services for the cannabis industry. The company was formerly known as Abattis Biologix Corporation and changed its name to Abattis Bioceuticals Corporation in September 2012. Abattis Bioceuticals Corp. was incorporated in 1997 and is headquartered in Vancouver, Canada.

4Front Ventures stock logo

4Front Ventures OTCMKTS:FFNTF

4Front Ventures Corp. owns and manages licensed cannabis facilities in state-licensed markets in the United States. The company operates through THC Cannabis and CBD Wellness segments. THC Cannabis segment engages in the cultivation, production, manufacturing, and distribution of THC cannabis products to owned dispensaries and third party retailers; and provision of ancillary services. This segment sells equipment, supplies, and intellectual property to cannabis producers; and leases real estate properties. The CBD Wellness segment sells non-THC hemp derived products. In addition, it operates dispensaries in the Massachusetts, Illinois, and Michigan primarily under the MISSION brand name. 4Front Ventures Corp. was founded in 2011 and is based in Phoenix, Arizona.

Sanofi stock logo

Sanofi OTCMKTS:SNYNF

$85.25 0.00 (0.00%)
As of 07/6/2026 11:20 AM Eastern

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.